Interesting data and look forward to seeing the diabetic KD data. Some good developments recently in this space, particularly the renal benefits reported in large trials of SGLT-2 inhibitors in CKD whether caused by diabetes or other conditions. Where this DMX product fits, will have to see.
Definitely one to watch.
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-274
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.040(8.16%) |
Mkt cap ! $250.7M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 48.5¢ | 44.8¢ | $1.098M | 2.375M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 337999 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 17466 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |